All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C264 | Human anti-Beryllium sulfate T cell receptor (CB-C004), pCDTCR1 | CB-C004 | Human | FWIDLFETIG | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-C265 | Human anti-Beryllium sulfate T cell receptor (CB-C005), pCDTCR1 | CB-C005 | Human | FWIDLFETIG | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0120 | Human anti-Beryllium Sulfate T cell receptor (1041-3.3), pCDTCR1 | 1041-3.3 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0121 | Human anti-Beryllium Sulfate T cell receptor (1332-2), pCDTCR1 | 1332-2 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0122 | Human anti-Beryllium Sulfate T cell receptor (1332-2 Valpha R53A), pCDTCR1 | 1332-2 Valpha R53A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0123 | Human anti-Beryllium Sulfate T cell receptor (1332-2 Valpha S30A), pCDTCR1 | 1332-2 Valpha S30A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0127 | Human anti-Beryllium Sulfate T cell receptor (1332-22 Vbeta K101A), pCDTCR1 | 1332-22 Vbeta K101A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0128 | Human anti-Beryllium Sulfate T cell receptor (1332-22 Vbeta S99A), pCDTCR1 | 1332-22 Vbeta S99A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0129 | Human anti-Beryllium Sulfate T cell receptor (1332-28), pCDTCR1 | 1332-28 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0130 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha D54A), pCDTCR1 | 1332-28 Valpha D54A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0131 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha D55A), pCDTCR1 | 1332-28 Valpha D55A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0132 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha G57A), pCDTCR1 | 1332-28 Valpha G57A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0133 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Valpha G97A), pCDTCR1 | 1332-28 Valpha G97A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0134 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta E100A), pCDTCR1 | 1332-28 Vbeta E100A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0135 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta E48A), pCDTCR1 | 1332-28 Vbeta E48A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0136 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta E52A), pCDTCR1 | 1332-28 Vbeta E52A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0137 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta G98A), pCDTCR1 | 1332-28 Vbeta G98A | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0138 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta5/1332-2 Valpha9), pCDTCR1 | 1332-28 Vbeta5/1332-2 Valpha9 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0139 | Human anti-Beryllium Sulfate T cell receptor (1332-28 Vbeta5/1332-22 Valpha8), pCDTCR1 | 1332-28 Vbeta5/1332-22 Valpha8 | Human | Beryllium sulfate | HLA-DPB1*02:01 | Lentiviral vector | ||
TCR-YC0140 | Human anti-Beryllium Sulfate T cell receptor (AV22), pCDTCR1 | AV22 | Human | Beryllium atom | HLA-DPA1*01:03/DPB1*02:01 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION